Cargando…

Epithelial barriers in allergy and asthma

The respiratory epithelium provides a physical, functional, and immunologic barrier to protect the host from the potential harming effects of inhaled environmental particles and to guarantee maintenance of a healthy state of the host. When compromised, activation of immune/inflammatory responses aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellings, Peter W., Steelant, Brecht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270816/
https://www.ncbi.nlm.nih.gov/pubmed/32507228
http://dx.doi.org/10.1016/j.jaci.2020.04.010
_version_ 1783541966894530560
author Hellings, Peter W.
Steelant, Brecht
author_facet Hellings, Peter W.
Steelant, Brecht
author_sort Hellings, Peter W.
collection PubMed
description The respiratory epithelium provides a physical, functional, and immunologic barrier to protect the host from the potential harming effects of inhaled environmental particles and to guarantee maintenance of a healthy state of the host. When compromised, activation of immune/inflammatory responses against exogenous allergens, microbial substances, and pollutants might occur, rendering individuals prone to develop chronic inflammation as seen in allergic rhinitis, chronic rhinosinusitis, and asthma. The airway epithelium in asthma and upper airway diseases is dysfunctional due to disturbed tight junction formation. By putting the epithelial barrier to the forefront of the pathophysiology of airway inflammation, different approaches to diagnose and target epithelial barrier defects are currently being developed. Using single-cell transcriptomics, novel epithelial cell types are being unraveled that might play a role in chronicity of respiratory diseases. We here review and discuss the current understandings of epithelial barrier defects in type 2–driven chronic inflammation of the upper and lower airways, the estimated contribution of these novel identified epithelial cells to disease, and the current clinical challenges in relation to diagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma.
format Online
Article
Text
id pubmed-7270816
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-72708162020-06-05 Epithelial barriers in allergy and asthma Hellings, Peter W. Steelant, Brecht J Allergy Clin Immunol Clinical Reviews in Allergy and Immunology The respiratory epithelium provides a physical, functional, and immunologic barrier to protect the host from the potential harming effects of inhaled environmental particles and to guarantee maintenance of a healthy state of the host. When compromised, activation of immune/inflammatory responses against exogenous allergens, microbial substances, and pollutants might occur, rendering individuals prone to develop chronic inflammation as seen in allergic rhinitis, chronic rhinosinusitis, and asthma. The airway epithelium in asthma and upper airway diseases is dysfunctional due to disturbed tight junction formation. By putting the epithelial barrier to the forefront of the pathophysiology of airway inflammation, different approaches to diagnose and target epithelial barrier defects are currently being developed. Using single-cell transcriptomics, novel epithelial cell types are being unraveled that might play a role in chronicity of respiratory diseases. We here review and discuss the current understandings of epithelial barrier defects in type 2–driven chronic inflammation of the upper and lower airways, the estimated contribution of these novel identified epithelial cells to disease, and the current clinical challenges in relation to diagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology 2020-06 2020-06-04 /pmc/articles/PMC7270816/ /pubmed/32507228 http://dx.doi.org/10.1016/j.jaci.2020.04.010 Text en © 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Reviews in Allergy and Immunology
Hellings, Peter W.
Steelant, Brecht
Epithelial barriers in allergy and asthma
title Epithelial barriers in allergy and asthma
title_full Epithelial barriers in allergy and asthma
title_fullStr Epithelial barriers in allergy and asthma
title_full_unstemmed Epithelial barriers in allergy and asthma
title_short Epithelial barriers in allergy and asthma
title_sort epithelial barriers in allergy and asthma
topic Clinical Reviews in Allergy and Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270816/
https://www.ncbi.nlm.nih.gov/pubmed/32507228
http://dx.doi.org/10.1016/j.jaci.2020.04.010
work_keys_str_mv AT hellingspeterw epithelialbarriersinallergyandasthma
AT steelantbrecht epithelialbarriersinallergyandasthma